Indication

soft tissue sarcoma of the extremity

1 clinical trial

1 drug

Clinical trial

SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

Status: Active (not recruiting), Estimated PCD: 2025-09-01

Drug